XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue recognition (Tables)
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue The Company's revenues disaggregated by operating segment and major sources for the three and six months ended June 30, 2024 and 2023 were as follows:
Three Months Ended June 30, 2024Three Months Ended June 30, 2023
USGNon-USG TotalUSGNon-USG Total
Commercial Product sales$0.1 $119.9 $120.0 $0.3 $137.6 $137.9 
MCM Product sales30.6 32.8 63.4 150.2 14.1 164.3 
Bioservices:
Services (1)
— 64.5 64.5 — 26.4 26.4 
Leases— 0.2 0.2 — 2.7 2.7 
Total Bioservices$— $64.7 $64.7 $— $29.1 $29.1 
Contracts and grants6.6 — 6.6 4.6 2.0 6.6 
Total revenues$37.3 $217.4 $254.7 $155.1 $182.8 $337.9 
(1) Bioservices Services revenues for the three months ended June 30, 2024 include $50.0 million attributable to the confidential arbitration settlement (the “Settlement Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, related to the 2022 termination of manufacturing services agreement with Janssen (the “Janssen Agreement”). The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, “Litigation” for additional information related to the accounting treatment and settlement of the arbitration with Janssen.
Six Months Ended June 30, 2024Six Months Ended June 30, 2023
USGNon-USG TotalUSGNon-USG Total
Commercial Product sales$0.4 $238.1 $238.5 $0.3 $243.8 $244.1 
MCM Product sales144.7 74.1 218.8 176.3 25.2 201.5 
Bioservices:
Services (1)
— 82.8 82.8 — 39.0 39.0 
Leases— 0.4 0.4 — 4.5 4.5 
Total Bioservices$— $83.2 $83.2 $— $43.5 $43.5 
Contracts and grants14.0 0.6 14.6 9.5 3.6 13.1 
Total revenues$159.1 $396.0 $555.1 $186.1 $316.1 $502.2 
(1) Bioservices Services revenues for the six months ended June 30, 2024 include $50.0 million attributable to the Settlement Agreement. The revenue is related to raw materials purchased for the Janssen Agreement which Janssen had not reimbursed. See Note 16, “Litigation” for additional information related to the Settlement Agreement and its accounting treatment.
Schedule of Rollforward of Contract Liabilities The following table presents the roll forward of the contract liability balances:
Contract Liabilities
Balance at December 31, 2023$29.9 
Balance at June 30, 2024$9.7 
Revenue recognized in the period from amounts included in contract liability at the beginning of the period:$25.0 
Schedule of Accounts Receivable, Net
Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:
June 30, 2024December 31, 2023
Accounts receivable:
Billed$120.7 $141.8 
Unbilled82.5 51.4 
Allowance for expected credit losses(6.9)(2.2)
Accounts receivable, net$196.3 $191.0